Attention www.globalkeysolutions.net is now www.keypedia.com, read the full press release here.
KeyPedia LogoKeyPedia Icon
  1. Home
  2. /
  3. Records
  4. /
  5. Warning Letter
  6. /
  7. Intas Pharmaceuticals Limited
WARNING LETTER
•Intas Pharmaceuticals Limited•September 17, 2025

Intas Pharmaceuticals Limited – FDA Warning Letter, Sep 17, 2025

Record Details

On March 30, 2026, the FDA issued a warning letter to Intas Pharmaceuticals Limited following an inspection of its manufacturing facility in Dehradun, India, conducted between September 8 and 17, 2025. The document outlines significant failures to comply with Current Good Manufacturing Practice (CGMP) regulations, leading the FDA to classify the firm"s drug products as adulterated under the Federal Food, Drug, and Cosmetic Act. The primary violations include inadequate investigations into out-of-specification results for subpotent tablet batches, which resulted in multiple product recalls and ineffective corrective actions. Additionally, the FDA identified serious data integrity concerns, noting that quality assurance staff instructed software vendors to modify electronic batch records without capturing those changes in audit trails. The company’s quality control unit was also found to have failed in its oversight responsibilities. To rectify these issues, the FDA requires Intas Pharmaceuticals to provide a comprehensive impact assessment for affected products, undergo an independent third-party review of its investigation and corrective action programs, and perform a retrospective audit of all software-related communications and batch record modifications. The company was given 15 working days to respond with a detailed plan for remediation, with the FDA warning that failure to address these deficiencies may lead to the withholding of new product approvals or the refusal of drug shipments into the United States.

Company
Intas Pharmaceuticals Limited
Inspection date
September 17, 2025
Product type
drugs
Office
Center for Drug Evaluation and Research
Person
  • Francis Godwin (Director)
View Company Profile

ID · 5823afb5-cd04-4920-9a5a-ce851b44651c

Violation Codes9
FD&C Act 801(a)(3)FD&C Act 501(a)(2)(B)21 CFR 21121 CFR 211(c)(2)21 CFR 21021 U.S.C. 381(a)(3)21 U.S.C. 356C(b)21 CFR 211.2221 U.S.C. 351(a)(2)(B)

Full citation text and observation details available on the Dashboard.

Other documents for Intas Pharmaceuticals Limited
  • 483 - 2025-02-14February 14, 2025
  • 483 - 2024-01-24January 24, 2024
  • 483 - 2023-12-07December 7, 2023
  • 483 - 2023-05-12May 12, 2023
  • 483 - 2022-12-02December 2, 2022

Your cart

Your cart is empty.

Browse public document pages and click Buy this document. We'll ask for your email at checkout, no account needed up front.

Browse documents

Discuss this record with AI

KeyPedia

ChatGPT

Claude

Perplexity

Grok

Copilot

Document or profile

One record shows the event. A profile shows the pattern.

Buy this document for the source file and details behind this single event.

Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.

Explore Intas Pharmaceuticals Limited
KeyPedia
Regulatory Data Transformed
Stay in the loop

KRA score changes, company updates and news. About monthly, unsubscribe anytime.

Contact
New York Office:
370 Jay Street 7th Floor
Brooklyn, NY 11201
Scranton Office:
Scranton Enterprise Center, Suite 217
201 Lackawanna Avenue
Scranton, PA, 18503
🇺🇸+1 917-789-5099
🇪🇺+48 532-447-507
info@keypedia.com
Quick Links
HomePlatform OverviewMedia
KeyPedia™ Lite
Browse HubDatabase DirectoryRecordsCompaniesOfficesPeopleCareersAbout UsFounding TeamMeet Our ExpertsPartners
Legal & Ethics
Privacy PolicyTerms of ServiceOur Values & MissionCode of Ethics & AI Policy
©2026 KeyPedia™ | Global Key Solutions Corp. All rights reserved.